{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:39:52Z","timestamp":1790836792057,"version":"4.1.0"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81401663"],"award-info":[{"award-number":["81401663"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771688"],"award-info":[{"award-number":["81771688"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GK1949"],"award-info":[{"award-number":["GK1949"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR60"],"award-info":[{"award-number":["TRR60"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02308","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T01:12:40Z","timestamp":1569287560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response"],"prefix":"10.3389","volume":"10","author":[{"given":"Zhiyong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shicheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengji","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S0016-5085(99)70289-1","article-title":"Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection","volume":"117","author":"Maini","year":"1999","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J Virol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2005.12.022","article-title":"Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans","volume":"45","author":"Sprengers","year":"2006","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nm.4275","article-title":"Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B","volume":"23","author":"Fisicaro","year":"2017","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are defective in hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1172\/JCI121957","article-title":"PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection","volume":"128","author":"Salimzadeh","year":"2018","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.015","article-title":"Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B","author":"Le Bert","year":"2019","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0130209","DOI":"10.1371\/journal.pone.0130209","article-title":"Total hepatitis B core antigen antibody, a quantitative non-invasive marker of hepatitis B virus induced liver disease","volume":"10","author":"Yuan","year":"2015","journal-title":"PLoS ONE."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1038\/s41598-017-03102-3","article-title":"Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/gutjnl-2014-308546","article-title":"Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues","volume":"65","author":"Fan","year":"2016","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/jvh.12626","article-title":"Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir","volume":"24","author":"Xu","year":"2017","journal-title":"J Viral Hepat"},{"key":"B17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2147\/IDR.S163038","article-title":"Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs","volume":"11","author":"Cai","year":"2018","journal-title":"Infect Drug Resist"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00535-010-0331-4","article-title":"Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy","volume":"46","author":"Kusumoto","year":"2011","journal-title":"J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/hep.29082","article-title":"Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis","volume":"66","author":"Paul","year":"2017","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.coviro.2018.04.002","article-title":"Viral envelope-specific antibodies in chronic hepatitis B virus infection","volume":"30","author":"Corti","year":"2018","journal-title":"Curr Opin Virol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1080\/21645515.2017.1319021","article-title":"Antibody-mediated immunotherapy against chronic hepatitis B virus infection","volume":"13","author":"Gao","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30788","article-title":"Baseline level of hepatitis B core antibody predicts spontaneous HBeAg seroconversion in HBeAg-positive children with a normal ALT level","author":"Chen","year":"2019","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hep.27805","article-title":"Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells","volume":"62","author":"Vanwolleghem","year":"2015","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"8766","DOI":"10.1073\/pnas.1003854107","article-title":"B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure","volume":"107","author":"Farci","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"E11369","DOI":"10.1073\/pnas.1809028115","article-title":"Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure","volume":"115","author":"Chen","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jim.2006.07.016","article-title":"Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay","volume":"315","author":"Tuaillon","year":"2006","journal-title":"J Immunol Methods"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.1016\/j.vaccine.2010.07.058","article-title":"Investigation of memory B cell responses to hepatitis B surface antigen in health care workers considered as non-responders to vaccination","volume":"28","author":"Valats","year":"2010","journal-title":"Vaccine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1086\/591094","article-title":"Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus","volume":"198","author":"Ward","year":"2008","journal-title":"J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1172\/JCI124098","article-title":"Entering the spotlight: hepatitis B surface antigen-specific B cells","volume":"128","author":"Neumann-Haefelin","year":"2018","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"15296","DOI":"10.1038\/s41598-018-33719-x","article-title":"HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis","volume":"8","author":"Poonia","year":"2018","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jhep.2010.10.016","article-title":"Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections","volume":"55","author":"Oliviero","year":"2011","journal-title":"J Hepatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/cmi.2015.25","article-title":"Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients","volume":"12","author":"Xu","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1172\/JCI116497","article-title":"The serology of chronic hepatitis B infection revisited","volume":"91","author":"Maruyama","year":"1993","journal-title":"J Clin Invest"},{"key":"B38","first-page":"376","article-title":"Antigen-specific detection of HBsAG-containing immune complexes in the course of hepatitis B virus infection","volume":"37","author":"Pernice","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1086\/513200","article-title":"Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection","volume":"44","author":"Zhang","year":"2007","journal-title":"Clin Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1128\/JVI.80.6.2968-2975.2006","article-title":"Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of \u201ca\u201d determinant variants","volume":"80","author":"Lada","year":"2006","journal-title":"J Virol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2893.2010.01322.x","article-title":"Elimination of hepatitis B virus surface antigen and appearance of neutralizing antibodies in chronically infected patients without viral clearance","volume":"18","author":"Zhang","year":"2011","journal-title":"J Viral Hepat"},{"key":"B42","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0140-6736(81)90832-1","article-title":"Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial","volume":"2","author":"Beasley","year":"1981","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1053\/jhep.2000.19789","article-title":"Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review","volume":"32","author":"Shouval","year":"2000","journal-title":"Hepatology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1034\/j.1600-0676.2001.021003207.x","article-title":"Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients","volume":"21","author":"van Nunen","year":"2001","journal-title":"Liver"},{"key":"B45","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1053\/jhep.2002.31867","article-title":"Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties","volume":"35","author":"Galun","year":"2002","journal-title":"Hepatology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1046\/j.1365-2893.2002.00337.x","article-title":"Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?","volume":"9","author":"van Nunen","year":"2002","journal-title":"J Viral Hepat"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00535-016-1189-x","article-title":"Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection","volume":"51","author":"Tsuge","year":"2016","journal-title":"J Gastroenterol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(94)91384-6","article-title":"Specific vaccine therapy in chronic hepatitis B infection","volume":"344","author":"Pol","year":"1994","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0168-8278(01)00028-9","article-title":"Efficacy and limitations of a specific immunotherapy in chronic hepatitis B","volume":"34","author":"Pol","year":"2001","journal-title":"J Hepatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e2565","DOI":"10.1371\/journal.pone.0002565","article-title":"A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients","volume":"3","author":"Xu","year":"2008","journal-title":"PLoS ONE."},{"key":"B51","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings","volume":"59","author":"Xu","year":"2013","journal-title":"J Hepatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1172\/JCI3731","article-title":"Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B","volume":"102","author":"Boni","year":"1998","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","article-title":"Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B","volume":"39","author":"Boni","year":"2003","journal-title":"J Hepatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","article-title":"Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine","volume":"25","author":"Vandepapeliere","year":"2007","journal-title":"Vaccine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/0264-410X(94)90155-4","article-title":"Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines","volume":"12","author":"Shouval","year":"1994","journal-title":"Vaccine"},{"key":"B57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0168-8278(00)00082-9","article-title":"Rapid seroprotection against hepatitis B following the first dose of a Pre-S1\/Pre-S2\/S vaccine","volume":"34","author":"Shapira","year":"2001","journal-title":"J Hepatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1128\/AAC.00276-09","article-title":"Randomized controlled study investigating viral suppression and serological response following pre-S1\/pre-S2\/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B","volume":"53","author":"Hoa","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.5009\/gnl18425","article-title":"New biomarkers of chronic hepatitis B","author":"Mak","year":"2019","journal-title":"Gut Liver"},{"key":"B60","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J Hepatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/jvh.13061","article-title":"Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA","volume":"26","author":"Chen","year":"2019","journal-title":"J Viral Hepat"},{"key":"B62","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/apt.15108","article-title":"Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues","volume":"49","author":"Hosaka","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13191","article-title":"Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma","author":"To","year":"2019","journal-title":"J Viral Hepat"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jhep.2011.06.006","article-title":"Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report","volume":"55","author":"Chan","year":"2011","journal-title":"J Hepatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00535-012-0668-y","article-title":"Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog","volume":"48","author":"Tseng","year":"2013","journal-title":"J Gastroenterol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J Hepatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"935295","DOI":"10.1155\/2013\/935295","article-title":"Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection","volume":"2013","author":"Kondo","year":"2013","journal-title":"ISRN Gastroenterol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coviro.2018.04.003","article-title":"Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination","volume":"30","author":"Dembek","year":"2018","journal-title":"Curr Opin Virol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","article-title":"Mechanisms of hepatitis B virus persistence","volume":"26","author":"Tsai","year":"2018","journal-title":"Trends Microbiol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/hep.22751","article-title":"Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells","volume":"49","author":"Wu","year":"2009","journal-title":"Hepatology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/jvh.12216","article-title":"Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen","volume":"21","author":"Jiang","year":"2014","journal-title":"J Viral Hepat"},{"key":"B72","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2567.2008.02896.x","article-title":"Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus","volume":"126","author":"Op den Brouw","year":"2009","journal-title":"Immunology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1172\/JCI66043","article-title":"Mobilizing monocytes to cross-present circulating viral antigen in chronic infection","volume":"123","author":"Gehring","year":"2013","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.1128\/JVI.78.11.5707-5719.2004","article-title":"Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy","volume":"78","author":"Webster","year":"2004","journal-title":"J Virol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J Virol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1038\/emi.2013.14","article-title":"T-cell responses in hepatitis B and C virus infection: similarities and differences","volume":"2","author":"Schmidt","year":"2013","journal-title":"Emerg Microbes Infect"},{"key":"B77","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.4049\/jimmunol.1501362","article-title":"Polarization of monocytic myeloid-derived suppressor cells by hepatitis B surface antigen is mediated via ERK\/IL-6\/STAT3 signaling feedback and restrains the activation of T cells in chronic hepatitis B virus infection","volume":"195","author":"Fang","year":"2015","journal-title":"J Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/apt.15226","article-title":"Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy","volume":"49","author":"Pal","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/hep.29155","article-title":"Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models","volume":"66","author":"Kosinska","year":"2017","journal-title":"Hepatology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3851\/IMP2580","article-title":"Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-alpha2a and adefovir","volume":"18","author":"Takkenberg","year":"2013","journal-title":"Antivir Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/hep.29213","article-title":"A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha","volume":"66","author":"Cao","year":"2017","journal-title":"Hepatology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"13383","DOI":"10.1038\/s41598-017-13747-9","article-title":"Switching to PegIFNalpha-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs","volume":"7","author":"Huang","year":"2017","journal-title":"Sci Rep"},{"key":"B83","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jhep.2013.06.007","article-title":"Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment","volume":"59","author":"Seto","year":"2013","journal-title":"J Hepatol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J Hepatol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/apt.14629","article-title":"Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance","volume":"47","author":"Qiu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B89","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12072-019-09956-1","article-title":"Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study","volume":"13","author":"Wu","year":"2019","journal-title":"Hepatol Int"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/infdis\/jiv180","article-title":"Natural killer cell characteristics in patients with chronic hepatitis B virus (HBV) infection are associated with HBV surface antigen clearance after combination treatment with pegylated interferon alfa-2a and adefovir","volume":"212","author":"Stelma","year":"2015","journal-title":"J Infect Dis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/jvh.12820","article-title":"Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: a randomized study","volume":"25","author":"Cannizzo","year":"2018","journal-title":"J Viral Hepat"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/infdis\/jiy097","article-title":"Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss","volume":"217","author":"Zimmer","year":"2018","journal-title":"J Infect Dis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","article-title":"Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"69","author":"Rinker","year":"2018","journal-title":"J Hepatol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1053\/j.gastro.2019.01.015","article-title":"Hepatitis B surface antigen loss: too little, too late and the challenge for the future","volume":"156","author":"Dusheiko","year":"2019","journal-title":"Gastroenterology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.antiviral.2015.06.019","article-title":"Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent","volume":"121","author":"Gish","year":"2015","journal-title":"Antiviral Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jhep.2018.03.012","article-title":"Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients","volume":"69","author":"Turner","year":"2018","journal-title":"J Hepatol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.antiviral.2016.07.004","article-title":"Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection","volume":"133","author":"Vaillant","year":"2016","journal-title":"Antiviral Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1021\/acsinfecdis.8b00156","article-title":"REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection","volume":"5","author":"Vaillant","year":"2019","journal-title":"ACS Infect Dis"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e0156667","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS ONE."},{"key":"B102","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1080\/19420862.2015.1134409","article-title":"A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect","volume":"8","author":"Wang","year":"2016","journal-title":"MAbs"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e26738","DOI":"10.7554\/eLife.26738","article-title":"A potent human neutralizing antibody Fc-dependently reduces established HBV infections","volume":"6","author":"Li","year":"2017","journal-title":"Elife"},{"key":"B105","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/gutjnl-2014-308964","article-title":"Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen","volume":"65","author":"Zhang","year":"2016","journal-title":"Gut"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317725","article-title":"A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice","author":"Zhang","year":"2019","journal-title":"Gut"},{"key":"B107","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/jmv.24091","article-title":"The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection","volume":"87","author":"Lee","year":"2015","journal-title":"J Med Virol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/jhep.2001.27564","article-title":"Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines","volume":"34","author":"Zuckerman","year":"2001","journal-title":"Hepatology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00004836-200310000-00012","article-title":"The lack of effect of therapeutic vaccination with a pre-S2\/S HBV vaccine in the immune tolerant phase of chronic HBV infection","volume":"37","author":"Yalcin","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s15010-003-3187-1","article-title":"Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial","volume":"31","author":"Yalcin","year":"2003","journal-title":"Infection"},{"key":"B111","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/j.1440-1746.2004.03358.x","article-title":"Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B","volume":"19","author":"Helvaci","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ijid.2006.09.010","article-title":"Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens","volume":"11","author":"Betancourt","year":"2007","journal-title":"Int J Infect Dis"},{"key":"B113","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s12072-013-9486-4","article-title":"Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B","volume":"7","author":"Al-Mahtab","year":"2013","journal-title":"Hepatol Int"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e0201236","DOI":"10.1371\/journal.pone.0201236","article-title":"Treatment of chronic hepatitis B naive patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)","volume":"13","author":"Al Mahtab","year":"2018","journal-title":"PLoS ONE."},{"key":"B115","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3389\/fimmu.2017.00775","article-title":"TLR7\/TLR9- and B cell receptor-signaling crosstalk: promotion of potentially dangerous B cells","volume":"8","author":"Suthers","year":"2017","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.4049\/jimmunol.0903949","article-title":"Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner","volume":"184","author":"Bessa","year":"2010","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3389\/fimmu.2017.01833","article-title":"Co-stimulation of BCR and Toll-like receptor 7 increases somatic hypermutation, memory B cell formation, and secondary antibody response to protein antigen","volume":"8","author":"Castiblanco","year":"2017","journal-title":"Front Immunol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.4049\/jimmunol.178.4.2415","article-title":"TLR9 signaling in B cells determines class switch recombination to IgG2a","volume":"178","author":"Jegerlehner","year":"2007","journal-title":"J Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.immuni.2011.01.011","article-title":"Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response","volume":"34","author":"Hou","year":"2011","journal-title":"Immunity"},{"key":"B120","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/cmi.2014.112","article-title":"Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses","volume":"12","author":"Ma","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I\/II study","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.vaccine.2004.07.014","article-title":"Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response","volume":"23","author":"Siegrist","year":"2004","journal-title":"Vaccine"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1016\/j.vaccine.2012.01.087","article-title":"Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18\u201355 years of age","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"B124","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.vaccine.2005.08.095","article-title":"Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults","volume":"24","author":"Halperin","year":"2006","journal-title":"Vaccine"},{"key":"B125","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1586\/erv.10.162","article-title":"Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV safety and efficacy","volume":"10","author":"Cooper","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/01.aids.0000183514.37513.d2","article-title":"CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults","volume":"19","author":"Cooper","year":"2005","journal-title":"AIDS"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1086\/533467","article-title":"CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years","volume":"46","author":"Cooper","year":"2008","journal-title":"Clin Infect Dis"},{"key":"B128","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s12072-018-9890-x","article-title":"Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study","volume":"12","author":"Lai","year":"2018","journal-title":"Hepatol Int"},{"key":"B129","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4172\/2332-0877.1000390","article-title":"Induction of functional control in chronic hepatitis B patients with low level HBsAg using a combination of a PreS1\/S2\/S HBV vaccine (Sci-BVacTM) and a nucleoside analogue","volume":"7","author":"Roggendorf H","year":"2019","journal-title":"J Infect Dis Ther"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02308\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T01:12:43Z","timestamp":1569287563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02308\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,24]]},"references-count":130,"alternative-id":["10.3389\/fimmu.2019.02308"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02308","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,24]]},"article-number":"2308"}}